In particular for MELAS, ccf-mtDNA represents a promising biomarker in evaluating the efficacy of recently proposed therapies aimed at preventing SLEs, such as arginine, citrulline, and taurine supplementation [33, 34]. Here, PITX1 is linked to MELAS.